Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Transkriptioner
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet

DanCann Pharma

Under 1K följer bolaget
Översikt
Investerarkonsensus

DanCann Pharma is a Danish life science company focused on discovering, developing, manufacturing, and commercialization of novel cannabinoid therapeutic products for medical use. The company was founded in 2018 due to the poor access for cannabinoid-based drugs and pharmaceuticals and with the purpose of developing and supplying medical cannabis, with a focus on consistency and quality provided by state-of-the-art and newly constructed manufacturing facilities (called Biotech Pharm1) which expect to be approved by the Danish authorities during 2022. DanCann recently acquired the Danish distributor of medical cannabis products, CannGros after which DanCann is now a fully vertical integrated operator within the market of cannabis for medical use, having development, manufacturing, and commercialization capabilities in-house.

Läs mera
Alla
Analys
Webcasts
Pressmeddelanden
Tredje part
VisarAlla typer av innehåll
Regulatoriskt pressmeddelande2026-01-13 07:00

DanCann Pharma A/S: No warrants exercised in extraordinary exercise period in connection with delisting

DanCann Pharma
Regulatoriskt pressmeddelande2026-01-08 08:10

Spotlight Stock Market has approved DanCann Pharma A/S' application for a voluntary delisting

DanCann Pharma
Regulatoriskt pressmeddelande2026-01-07 11:00

DanCann Pharma A/S has today applied for a voluntary delisting from Spotlight Stock Market

DanCann Pharma

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

Inderes användarkonto
Ger dig möjlighet att följa bolag och beställa notifikationer
Tillgång till analytikerkommentarer och rekommendationer
Tillgång till vårt aktiescreeningsverktyg och andra populära verktyg
Skapa användarkonto
Regulatoriskt pressmeddelande2026-01-06 12:00

DanCann Pharma A/S: Chairman's New Year Update

DanCann Pharma
Regulatoriskt pressmeddelande2025-12-29 07:00

DanCann Pharma A/S: Extraordinary exercise period for warrants commences today as a result application for delisting

DanCann Pharma
Regulatoriskt pressmeddelande2025-11-17 16:01

DanCann Pharma A/S Completes Sale of CannGros ApS to StenoCare A/S through Equity Transaction

DanCann Pharma
Regulatoriskt pressmeddelande2025-10-27 17:00

DanCann Pharma A/S delivers Q3 2025 Highlights - Leadership Transition, Strategic Progress, and Path Toward Delisting

DanCann Pharma
Regulatoriskt pressmeddelande2025-10-21 08:00

Minutes of Extraordinary General Meeting held in DanCann Pharma A/S

DanCann Pharma
Regulatoriskt pressmeddelande2025-10-06 16:05

DanCann Pharma A/S: Chairman's Letter to the Shareholders - CEO Transition and Voluntary Delisting

DanCann Pharma
Regulatoriskt pressmeddelande2025-10-06 16:01

DanCann Pharma: NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S

DanCann Pharma
Regulatoriskt pressmeddelande2025-10-06 16:00

DanCann Pharma A/S has resolved to apply for delisting from Spotlight Stock Market, subject to approval by the general meeting

DanCann Pharma
Regulatoriskt pressmeddelande2025-08-25 17:00

DanCann Pharma A/S: Delivers Q2-2025 Highlights

DanCann Pharma
Regulatoriskt pressmeddelande2025-07-09 20:15

DanCann Pharma A/S shares supplementary details of the obtained bridge loan

DanCann Pharma
Regulatoriskt pressmeddelande2025-07-09 09:00

DanCann Pharma A/S signs a conditional sales agreement for the sale of manufacturing site (BP1), secures bridge financing, and launches new strategy, Maturity2028

DanCann Pharma
Regulatoriskt pressmeddelande2025-05-23 15:05

DanCann Pharma A/S: Delivers Q1-2025 Highlights - Expands Prescription (Rx) Portfolio, Eyes Consumer Health Market Entry (OTC)

DanCann Pharma
Regulatoriskt pressmeddelande2025-05-23 15:05

DanCann Pharma A/S: Præsenterer højdepunkter fra 1. kvartal 2025 - Udvider receptportefølje (Rx) og forbereder indtræden på markedet for håndkøbsprodukter (OTC)

DanCann Pharma
Regulatoriskt pressmeddelande2025-05-19 06:30

DanCann Pharma A/S: Receives Regulatory Approval for Bedrolite® and Bedrobinol® from the Danish Medicines Agency under the Danish Pilot Programme

DanCann Pharma
Regulatoriskt pressmeddelande2025-04-25 06:45

DanCann Pharma A/S: Adoption of Permanent Medicinal Cannabis Legislation in Denmark Completed

DanCann Pharma
Regulatoriskt pressmeddelande2025-04-24 09:30

DanCann Pharma A/S: Updated Financial Calendar for the Remainder of 2025

DanCann Pharma
Regulatoriskt pressmeddelande2025-04-24 09:15

DanCann Pharma: DANCANN PHARMA A/S: MINUTES OF ANNUAL GENERAL MEETING

DanCann Pharma
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.